Advancing Engineered Phages Toward Clinical Reality
- Presenting results of FHD clinical study and clinical development plan for SNIPR001, a cocktail of engineered, CRISPR-armed phages targeting E. coli
- Discussing other uses of SNIPR001 based on in vivo preclinical data and a case study
- Outlining the critical steps toward building a regulatory and clinical evidence base that can support the first approvals of engineered phage products